鼓励创新药等药品进零售药店、支持零售药店进行兼并重组......9部门出台18项硬举措促进药品零售行业发展

Core Viewpoint - The Ministry of Commerce, along with eight other departments, has issued an opinion aimed at promoting high-quality development in the pharmaceutical retail industry through 18 specific measures across five dimensions, focusing on enhancing professional services, health promotion, emergency supply, industry structure optimization, and industry order regulation [1] Group 1: Improvement of Pharmaceutical Services - The opinion emphasizes the promotion of prescription circulation to enhance the purchasing experience, advocating for the improvement of external prescription circulation mechanisms and the optimization of settlement rules [3] - It encourages the establishment of electronic prescription circulation platforms and the integration of retail pharmacies with medical institutions to facilitate prescription transfers [3] - The opinion aims to optimize the settlement methods between medical insurance funds and retail pharmacies, thereby improving efficiency and resource allocation [3] Group 2: Industry Structure Optimization - The opinion encourages horizontal mergers and acquisitions among pharmaceutical retail enterprises and aims to streamline the licensing process for integrated pharmacies [4] - It supports the integration of supply chains through mergers and acquisitions in the wholesale sector, promoting a unified development of wholesale and retail [4] - The opinion is expected to drive industry consolidation and upgrade, leading to the formation of large-scale, competitive pharmaceutical retail enterprises [5] Group 3: Price Regulation and Consumer Protection - The opinion advocates for collaboration between pharmaceutical manufacturers and large distribution companies to standardize drug pricing systems and promote fair competition across regions [5] - It encourages the sale of innovative drugs and reference preparations through retail channels and the establishment of price monitoring tools for consumers [6] - The promotion of price comparison tools for insured drugs is seen as crucial for ensuring market price regulation and protecting consumer rights [6]